There are several genes that code for enzymes, including various forms of superoxide dismutase and glutathione peroxidase, that protect the cell against oxidative damage that, in turn, can lead to carcinogenesis. There are a few common genetic polymorphisms in these genes that lead to altered proteins. Three that have been identified are SOD2 Val-9Ala, GPX1 Pro198Leu, and the GPX1 GCG repeat (three alleles with four, five, or six repeats). The SOD2 variant has been associated with increased breast cancer risk in two studies. The GPX1 variants have not been studied with respect to breast cancer, but Pro198Leu has been associated with lung cancer. We conducted a case-control study of these three polymorphisms in incident, invasive breast cancer in Caucasian women under 55. There were 399 cases and 372 controls genotyped, of whom 488 were premenopausal, 208 postmenopausal, and 75 of unknown menopausal status. We were unable to replicate the previously observed association with SOD2 Val-9Ala and also found no association between breast cancer and GPX1 Pro198Leu. However, the allele of GPX1 containing four GCG repeats was significantly associated with breast cancer risk in premenopausal women (odds ratio, 1.55; 95% confidence interval, 1.04 -2.30 for carriers versus noncarriers). There is a significant trend of increasing risk with increasing number of alleles with four GCG repeats (P ‫؍‬ 0.03). This variant has not previously been reported to be associated with breast cancer.
Introduction
Oxidative stress from reactive oxygen species, which results in cellular and DNA damage, has been linked to cancer and other diseases of aging (1) (2) (3) (4) (5) (6) . The group of enzymes responsible to a large degree for endogenous antioxidant defense in the cell includes superoxide dismutase, catalase, and glutathione peroxidase (GPX).
There is a polymorphism in the SOD2 gene encoding manganese superoxide dismutase (MnSOD), which may have functional effects. This C to T substitution (at position 2734 of accession no. L34157) results in an amino acid change from valine to alanine at codon Ϫ9. This change occurs in the mitochondrial targeting sequence and likely affects transport of MnSOD to the mitochondria (7) . The alanine variant has been found more frequently in both pre-and postmenopausal breast cancer patients compared with controls in a study in Caucasian women (266 cases and 295 controls; Ref. 8) . This finding was replicated in a Finnish case-control study with 483 cases and 482 controls (9), but was not observed in another study with 261 cases and 370 controls (10) .
The isoform of GPX that is found in the mitochondria and that functions in the same pathway as MnSOD is encoded by the GPX1 gene. In this gene, variation in the number of GCG repeats (four, five, or six; at position 337 of accession no. NM_000581.1) has been identified resulting in a protein with a variable number of alanines (5, 6 , or 7 because of a neighboring GCC codon; Refs. 11, 12) . A substitution of C to T (at position 911 of accession no. NM_000581.1) in the GPX1 gene has also been detected, corresponding to an amino acid change from proline to leucine at position 198 (initially incorrectly assigned to position 197; Ref. 13 ). In the limited number of case-control studies examining GPX1 polymorphisms and cancer, no relationship was found between the GCG repeat and prostate cancer (267 cases and 260 controls; Ref. 14), but some evidence for an association between Pro198Leu genotype and lung cancer in smokers was observed (15) .
We conducted a case-control study to consider whether three identified common polymorphisms leading to protein alteration in antioxidant enzymes are associated with breast cancer in Caucasian women under age 55. These variants are SOD2 Val-9Ala, GPX1 Pro198Leu, and the GPX1 GCG repeat polymorphism. These GPX1 variants have not been previously studied with respect to breast cancer risk
Materials and Methods
A case-control study was conducted making use of the Ontario Familial Breast Cancer Registry (OFBCR) a participating site in the United States NIH Breast Cancer Family Registry. The OFBCR has been described more fully elsewhere (16) . Cases of invasive breast cancer, pathologically confirmed, and diagnosed between 1996 and 1998 in the province of Ontario were identified from the Ontario Cancer Registry within ϳ6 months of diagnosis in most cases. All female cases under 55, a random sample of female cases ages 55-69, and all male cases under age 80 were identified. However, the present study was restricted to women under 55 for two reasons. The number of older women available for inclusion was limited, and it was hypothesized that genetic alterations would play a stronger role in younger women. The Ontario Cancer Registry uses a passive, voluntary system of cancer registration, but it is estimated that ϳ99% of all breast cancer diagnoses in Ontario residents are captured based on a recent field study. 7 Physicians were contacted to obtain permission to contact patients, and permission was granted for 91% of cases (7668 of 8453). Only 1.7% (140) of the 8453 had died. Patients who could be contacted were then mailed a cancer family history questionnaire and 65% (4957) completed it (5% of the nonresponders had died). All of the respondents (excluding 1.6% who declined further contact or 0.4% who died after responding) who met a defined set of genetic risk criteria, and a random sample of 25% of those not meeting criteria, were selected to continue to participate in the OFBCR (n ϭ 2580). This participation included completing a mailed risk factor questionnaire (completed by 72% of all eligible; n ϭ 1848) and providing a blood sample (provided by 62% of all eligible; n ϭ 1601). Only 3% had died or were otherwise unable to provide a blood sample. For the present study, we restricted the sample to those who self-identified as white only and had provided blood with or without a questionnaire. Also, because of the 25% random sample of those who did not meet genetic risk criteria, we randomly sampled 25% of those who did meet genetic risk criteria to create a more generally representative sample of cases. A total of 459 white cases with blood available were selected. After exclusion of those with insufficient DNA or who could not be genotyped for other reasons, 399 cases were genotyped, 347 of whom also had risk factor questionnaire data available (246 premenopausal, 98 postmenopausal, and 3 unknown). Because there was loss at each stage, we were concerned about potential bias, particularly related to family history. However, response by the participants at all stages was not related to family history of breast and ovarian cancer (16, 17) . Race/ethnicity was a factor in response, but in general, Caucasians had higher response rates than nonCaucasians. In preliminary case-control analyses, increased risk has been observed with nulliparity and increased age at first birth as would be expected. Five-year survival after breast cancer diagnosis is high and very few potential participants were lost because of death.
Controls were identified by calling randomly selected residential telephone numbers from across the province of Ontario and were frequency-matched to all female OFBCR cases by 5-year age group. The number of telephone numbers was 14,653, but 1,101 (8%) were invalid and no contact could be made for 841 (6%). Of the 12,711 households contacted, 7,829 (62%) did not have an eligible individual. No information on eligibility was provided for 2,194 (17%) households. Of the 2,688 eligible individuals identified on the telephone, 1,726 (64%) completed the mailed risk factor questionnaire. Six hundred seventy-six women were asked to provide a blood sample; the women were randomly selected from those under 55 who had agreed to be approached about blood sampling (75% agreed), and blood samples were obtained from 419 (62%). Individuals who were not white were excluded from the analysis as were those with insufficient DNA or those subsequently found to be ineligible because of age. This left 372 controls (240 premenopausal, 110 postmenopausal, and 12 unknown) with genotypes available (370 for the GPX1 Pro198Leu variant).
The GPX1 Pro198Leu polymorphism was analyzed by 33 P]dATP (PE Biosystems), and 0.5 unit of HotStar TaqDNA Polymerase (Qiagen). PCR cycling conditions consisted of an initial 15-min incubation at 95°C for the activation of HotStar enzyme, followed by 2 cycles of 94°C for 30 s, 65°C for 30 s, and 72°C for 30 s, and 2 cycles of 94°C for 30 s, 63°C for 30 s, and 72°C for 30 s, followed by 30 cycles of 94°C for 30 s, and 58°C for 60 s. The PCR products from specimens were analyzed on 1ϫ molecular detection enhancement gels (BioWhittaker Molecular Applications) at room temperature, at 600 v for ϳ16 h. All gels were dried and subject to autoradiography.
A panel of samples, representing different genotypes of each variant, were amplified and subjected to sequencing analysis before the genotyping. The same set of primers used for sequencing were also used for genotyping the specimens. Positive control specimens with known genotypes and expected mobility patterns were included in each experiment for all of the polymorphisms studied. Multiple negative DNA control specimens were also used in each genotyping experiment to eliminate any false-positive results. For validation purposes, 10% of breast cancer cases and population controls were randomly selected and regenotyped.
We analyzed the genotypes for all individuals combined and for premenopausal women separately. In the subgroup analyses, women who did not complete the risk factor questionnaire or whose menopausal status could not be determined based on their responses were excluded. Menopause was defined as no periods for 1 year or complete oophorectomy. Women who had a hysterectomy without bilateral oophorectomy or who were having periods but who were taking hormone replacement for menopause were considered unknown status. Unconditional logistic regression was used to generate odds ratios (ORs) and 95% confidence intervals by genotype. The trend for an increasing number of a specific allele was tested by coding for the number of alleles carried (0, 1, or 2).
Results
The age distribution of cases and controls, as shown in Table 1 , was quite similar as was the proportion who were premenopausal. As the number of postmenopausal women was relatively small leading to uncertain estimates, only results from all women combined (397 cases and 372 controls) as well as those who were known to be premenopausal (246 cases and 240 controls) are presented. Table 1 also shows the proportions of cases and controls with a first-degree relative with breast cancer. Approximately twice as many cases as controls have such a family history as would be expected. Table 2 shows the results for the SOD2 Val-9Ala variant. Unlike two previous studies, we did not see an increased risk for breast cancer associated with the alanine allele. This was true of all women under 55 as well as the premenopausal subgroup. Similarly, no significant association was observed between the GPX1 Pro198Leu variant and breast cancer ( Table 2) .
The variable number of GCG repeats in the GPX1 gene leads to three alleles, 4, 5, or 6 repeats, and six possible genotypes (Table 3) . Overall the genotypes including the four allele tended to be associated with estimates of higher risk, but this was not significant. When all carriers of the four alleles were combined and compared with all noncarriers, the confidence interval narrowed, but still included 1.00. However, this association was significant in premenopausal women in whom an OR of 1.55 (95% confidence interval, 1.04 -2.03) was observed for carriers of fewer repeats. There was also evidence (P ϭ 0.03) for a significant increasing trend with an increasing number of four alleles (0, 1, 2).
Discussion
Cellular defenses against oxidative damage are, like DNA repair, part of the available mechanisms preventing carcinogenesis. Of the genes coding for enzymes involved in this process, there are relatively few polymorphisms causing amino acid changes that have been identified. The SOD2 gene that codes for MnSOD has received the most attention. Two published studies found a significant association between the A allele (alanine) and breast cancer (8, 9) in Caucasian populations. Although these studies appear to be consistent, there are dif- Table 3 Odds ratios (ORs) and 95% confidence intervals (CIs) for the GPX1 GCG repeat in all women (n ϭ 771) and in premenopausal women (n ϭ 488) Genotype Controls, n (%) Cases, n (%) OR 95% CI ferences in the results. The study by Ambrosone et al. (8) found the association was stronger in homozygotes than in heterozygotes and stronger in premenopausal (OR ϭ 3.5) than in postmenopausal (OR ϭ 1.7) women. In contrast, Mitrunen et al. (9) , found little difference between homozygotes and heterozygotes and a slightly stronger effect in postmenopausal women (OR, 1.2 in premenopause; OR, 1.7 in postmenopause). In fact, the results for postmenopausal women are similar between the two studies, but results for premenopauasal women differ. At least one other group has presented results that were negative for an association with this SOD2 variant (10) . If a small association occurs in postmenopauasal women, our study would not have been able to identify this because the majority of women in our sample were premenopausal and all were under age 55. As with Mitrunen et al., we did not find an association in this group. Few studies have considered a relationship between GPX1 variants and cancer, and none have considered these in breast cancer, although the enzyme plays an important role in the cellular antioxidant defenses. In our preliminary examination, we did not find a relationship between the GPX1 Pro198Leu variant and breast cancer. We did, however, observe a significantly increased risk of premenopausal breast cancer associated with the four GCG repeat allele compared with five or six repeats. The results were no longer significant when postmenopausal women were included. A test for trend associated with the increasing number of alleles with four repeats (2 or 1 versus 0) was also significant in premenopausal women (P ϭ 0.03). As in Moscow et al. (12) , we found that five GCG repeats always occurred with proline, forming a consistent haplotype, but this was not associated with altered breast cancer risk. Leucine occurred with both four and six GCG repeats, but only the instance of four repeats was associated with increased risk. Although located in the coding region, alanine repeats are not found in a known functional motif of the GPX protein sequence. However, different lengths of alanine repeats may potentially affect the folding or stability of this protein or its interaction with other proteins.
Although we restricted the sample to Caucasians, the possibility of persistent confounding (population stratification) cannot be entirely ruled out. However, it has been shown to be unlikely in North American Caucasians (18) . Of greater concern is whether the loss of participants at various stages of the data and sample collection resulted in a biased sample. For the OR estimates to be biased, participation would have to be associated with the genotypes of interest. If the participation bias was nondifferential between cases and controls, this would likely lead to an underestimate of effect. Although this is possible, there is no obvious reason why response should be related to either of these genotypes in either cases or controls unless this variant contributed to a family history of cancer, which, in turn, was related to participation. In general, we have not found that family history was associated with response at any stage of data and sample collection in cases (16, 17) . More complex scenarios are possible, including a relationship between response and an important, but unknown, interacting factor. Survival bias is not a major concern because very few eligible individuals died at each stage of the initial data and sample collection in the OFBCR.
In this particular sample, the number of postmenopausal women was too small and too selected to draw general conclusions. An association in premenopausal women is consistent with the concept that genetics will play a greater role in earlieronset disease. However, given the potential for bias in any single study, we consider the GPX1 GCG repeat result to be preliminary and requiring replication.
